Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDR1 | Q08345 | 15/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL781955 | 0.92 | DDR1 (0.36) | DDR1LMNAALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL29798955 | 0.92 | DDR1 (0.36) | DDR1LMNAALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL781957 | 0.92 | DDR1 (0.36) | DDR1LMNAALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL782106 | 0.86 | DDR1 (0.35) | DDR1 | |
| SCHEMBL29798823 | 0.86 | DDR1 (0.35) | DDR1 | |
| SCHEMBL782104 | 0.86 | DDR1 (0.35) | DDR1 | |
| SCHEMBL781952 | 0.84 | ALDH1A1 (0.40) | LMNAALDH1A1MAPK1SMN1; SMN2PKM | |
| SCHEMBL781954 | 0.84 | ALDH1A1 (0.40) | LMNAALDH1A1MAPK1SMN1; SMN2PKM | |
| SCHEMBL14692958 | 0.84 | DDR1 (0.37) | DDR1 | |
| SCHEMBL781526 | 0.82 | ALDH1A1 (0.38) | LMNAALDH1A1MAPK1SMN1; SMN2PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120071479-A1 | PYRAZINE DERIVATIVES AS ENAC BLOCKERS | NOVARTIS AG (CH) | 2012-03-22 | — | — | US | disclosed |
| US-20120071479-A1 | PYRAZINE DERIVATIVES AS ENAC BLOCKERS | NOVARTIS AG (CH) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071479-A1 | PYRAZINE DERIVATIVES AS ENAC BLOCKERS | REN, SCNN1B, SCN5A | DDR1 873/4885LMNA 2950/4885ALDH1A1 2428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.